Gender | Locally advanced breast cancer HER2/Neu Positive | Secondary malignant neoplasm of female breast HER2/Neu Positive
Item
females with pathologically determined locally advanced or metastatic human epidermal growth factor receptor 2 positive (her2/neu+) breast cancer
boolean
C0079399 (UMLS CUI [1])
C3495949 (UMLS CUI [2,1])
C2348909 (UMLS CUI [2,2])
C0346993 (UMLS CUI [3,1])
C2348909 (UMLS CUI [3,2])
Chemotherapy | taxane | trastuzumab | Disease Progression
Item
have progressed after treatment with chemotherapy including a taxane and trastuzumab
boolean
C0392920 (UMLS CUI [1])
C0215136 (UMLS CUI [2])
C0728747 (UMLS CUI [3])
C0242656 (UMLS CUI [4])
Measurable Disease
Item
must have measurable disease by recist
boolean
C1513041 (UMLS CUI [1])
ECOG performance status
Item
ecog ps of 0,1, or 2
boolean
C1520224 (UMLS CUI [1])
Left ventricular ejection fraction MUGA scan | Left ventricular ejection fraction Echocardiography
Item
muga scan or echocardiogram results show left ventricular ejection fraction greater than or equal to 50%
boolean
C0428772 (UMLS CUI [1,1])
C0521317 (UMLS CUI [1,2])
C0428772 (UMLS CUI [2,1])
C0013516 (UMLS CUI [2,2])
Therapeutic radiology procedure | Chemotherapy | Non-Cytotoxic Agent Investigational
Item
radiation therapy within 2 weeks, chemotherapy within 3 weeks, or noncytoxic investigational agents within 4 weeks of initiating study treatment
boolean
C1522449 (UMLS CUI [1])
C0392920 (UMLS CUI [2])
C2827065 (UMLS CUI [3,1])
C1517586 (UMLS CUI [3,2])
Heart Disease New York Heart Association Classification
Item
evidence of new york heart association class iii or greater cardiac disease
boolean
C0018799 (UMLS CUI [1,1])
C1275491 (UMLS CUI [1,2])
Myocardial Infarction | Cerebrovascular accident | Ventricular arrhythmia | Conduction abnormality Symptomatic
Item
history of mi, stroke, ventricular arrhythmia, or symptomatic conduction abnormality
boolean
C0027051 (UMLS CUI [1])
C0038454 (UMLS CUI [2])
C0085612 (UMLS CUI [3])
C0232219 (UMLS CUI [4,1])
C0231220 (UMLS CUI [4,2])
Prolonged QT interval Congenital
Item
history of congenital qt prolongation
boolean
C0151878 (UMLS CUI [1,1])
C1744681 (UMLS CUI [1,2])
Comorbidity Severe | Comorbidity Uncontrolled
Item
concurrent severe or uncontrolled medical disease
boolean
C0009488 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C0009488 (UMLS CUI [2,1])
C0205318 (UMLS CUI [2,2])
CNS metastases Symptomatic
Item
symptomatic central nervous system metastases
boolean
C0686377 (UMLS CUI [1,1])
C0231220 (UMLS CUI [1,2])
Pregnancy | Breast Feeding
Item
pregnant or nursing women
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Hypersensitivity apricoxib | Hypersensitivity lapatinib | Hypersensitivity capecitabine | Fluorouracil allergy | Allergy to sulfonamides | Aspirin allergy | Non-steroidal anti-inflammatory drug allergy | Intolerance to apricoxib | Intolerance to lapatinib | Intolerance to capecitabine | Intolerance to Fluorouracil | Intolerance to Sulfonamides | Intolerance to Aspirin | Intolerance to NSAIDS
Item
hypersensitivity or intolerance to apricoxib, lapatinib, capecitabine, 5-fu, sulfonamides, aspirin, or nsaids
boolean
C0020517 (UMLS CUI [1,1])
C1737955 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C1506770 (UMLS CUI [2,2])
C0020517 (UMLS CUI [3,1])
C0671970 (UMLS CUI [3,2])
C0570698 (UMLS CUI [4])
C0038757 (UMLS CUI [5])
C0004058 (UMLS CUI [6])
C0570537 (UMLS CUI [7])
C1744706 (UMLS CUI [8,1])
C1737955 (UMLS CUI [8,2])
C1744706 (UMLS CUI [9,1])
C1506770 (UMLS CUI [9,2])
C1744706 (UMLS CUI [10,1])
C0671970 (UMLS CUI [10,2])
C1744706 (UMLS CUI [11,1])
C0016360 (UMLS CUI [11,2])
C1744706 (UMLS CUI [12,1])
C0038760 (UMLS CUI [12,2])
C1744706 (UMLS CUI [13,1])
C0004057 (UMLS CUI [13,2])
C1744706 (UMLS CUI [14,1])
C0003211 (UMLS CUI [14,2])
Renal Insufficiency Severe
Item
severe renal insufficiency
boolean
C1565489 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
Upper gastrointestinal hemorrhage | Upper gastrointestinal tract Ulceration | UPPER GASTROINTESTINAL PERFORATION | CYP3A4 Inhibitors | CYP3A4 Inducers
Item
history of upper gi bleeding, ulceration, or perforation- concurrent use of potent cyp3a4 inhibitors and cyp3a4 inducers
boolean
C0041909 (UMLS CUI [1])
C1268997 (UMLS CUI [2,1])
C3887532 (UMLS CUI [2,2])
C0749862 (UMLS CUI [3])
C3850053 (UMLS CUI [4])
C3850041 (UMLS CUI [5])
capecitabine
Item
prior treatment with capecitabine
boolean
C0671970 (UMLS CUI [1])
Anti-Arrhythmia Agents
Item
patients on anti-arrhythmic treatment
boolean
C0003195 (UMLS CUI [1])
lapatinib
Item
prior lapatinib therapy
boolean
C1506770 (UMLS CUI [1])